Literature DB >> 28842427

Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy.

Roberta Cascella1, Giulia Fani1, Claudia Capitini1, Paola Rusmini2, Angelo Poletti2, Cristina Cecchi1, Fabrizio Chiti3.   

Abstract

Amyotrophic lateral sclerosis and frontotemporal lobar degeneration with ubiquitin-positive inclusions are neurodegenerative disorders that share the cytosolic deposition of TDP-43 (TAR DNA-binding protein 43) in the CNS. TDP-43 is well known as being actively degraded by both the proteasome and macroautophagy. The well-documented decrease in the efficiency of these clearance systems in aging and neurodegeneration, as well as the genetic evidence that many of the familial forms of TDP-43 proteinopathies involve genes that are associated with them, suggest that a failure of these protein degradation systems is a major factor that contributes to the onset of TDP-43-associated disorders. Here, we inserted preformed human TDP-43 aggregates in the cytosol of murine NSC34 and N2a cells in diffuse form and observed their degradation under conditions in which exogenous TDP-43 is not expressed and endogenous nuclear TDP-43 is not recruited, thereby allowing a time zero to be established in TDP-43 degradation and to observe its disposal kinetically and analytically. TDP-43 degradation was observed in the absence and presence of selective inhibitors and small interfering RNAs against the proteasome and autophagy. We found that cytosolic diffuse aggregates of TDP-43 can be distinguished in 3 different classes on the basis of their vulnerability to degradation, which contributed to the definition-with previous reports-of a total of 6 distinct classes of misfolded TDP-43 species that range from soluble monomer to undegradable macroaggregates. We also found that the proteasome and macroautophagy-degradable pools of TDP-43 are fully distinguishable, rather than in equilibrium between them on the time scale required for degradation, and that a significant crosstalk exists between the 2 degradation processes.-Cascella, R., Fani, G., Capitini, C., Rusmini, P., Poletti, A., Cecchi, C., Chiti, F. Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy. © FASEB.

Entities:  

Keywords:  ALS; FTLD-U; UPS; motor neuron disease; protein aggregation

Mesh:

Substances:

Year:  2017        PMID: 28842427     DOI: 10.1096/fj.201700292RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  16 in total

Review 1.  Mechanisms of TDP-43 Proteinopathy Onset and Propagation.

Authors:  Han-Jou Chen; Jacqueline C Mitchell
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

Review 2.  Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.

Authors:  Lindsey R Hayes; Petr Kalab
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 6.088

3.  Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.

Authors:  Paola Rusmini; Katia Cortese; Valeria Crippa; Riccardo Cristofani; Maria Elena Cicardi; Veronica Ferrari; Giulia Vezzoli; Barbara Tedesco; Marco Meroni; Elio Messi; Margherita Piccolella; Mariarita Galbiati; Massimiliano Garrè; Elena Morelli; Thomas Vaccari; Angelo Poletti
Journal:  Autophagy       Date:  2018-11-05       Impact factor: 16.016

Review 4.  Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.

Authors:  Alistair Wood; Yuval Gurfinkel; Nicole Polain; Wesley Lamont; Sarah Lyn Rea
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 5.  Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways.

Authors:  Mohamed A Eldeeb; Mohamed A Ragheb; Marwa H Soliman; Richard P Fahlman
Journal:  Neurotox Res       Date:  2022-01-18       Impact factor: 3.911

6.  Tdp-25 Routing to Autophagy and Proteasome Ameliorates its Aggregation in Amyotrophic Lateral Sclerosis Target Cells.

Authors:  Maria Elena Cicardi; Riccardo Cristofani; Paola Rusmini; Marco Meroni; Veronica Ferrari; Giulia Vezzoli; Barbara Tedesco; Margherita Piccolella; Elio Messi; Mariarita Galbiati; Alessandra Boncoraglio; Serena Carra; Valeria Crippa; Angelo Poletti
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

7.  TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response.

Authors:  Peng Wang; Jianwen Deng; Jie Dong; Jianghong Liu; Eileen H Bigio; Marsel Mesulam; Tao Wang; Lei Sun; Li Wang; Alan Yueh-Luen Lee; Warren A McGee; Xiaoping Chen; Kazuo Fushimi; Li Zhu; Jane Y Wu
Journal:  PLoS Genet       Date:  2019-05-17       Impact factor: 5.917

Review 8.  The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?

Authors:  Rudolf C Hergesheimer; Anna A Chami; Denis Reis de Assis; Patrick Vourc'h; Christian R Andres; Philippe Corcia; Débora Lanznaster; Hélène Blasco
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

Review 9.  Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.

Authors:  François Le Guerroué; Richard J Youle
Journal:  Cell Death Differ       Date:  2020-11-18       Impact factor: 12.067

10.  No association between proton pump inhibitor use and ALS risk: a nationwide nested case-control study.

Authors:  Hakan Cetin; Jiangwei Sun; Catarina Almqvist; Berthold Reichardt; Matthias Tomschik; Fritz Zimprich; Fang Fang; Caroline Ingre
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.